Trenonacog alfa - Aptevo Therapeutics

Drug Profile

Trenonacog alfa - Aptevo Therapeutics

Alternative Names: Coagulation Factor IX (Recombinant) - Aptevo Therapeutics; IB-1001; IXINITY; Nonacog-alfa biosimilar - Emergent BioSolutions; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - Emergent BioSolutions; Recombinant factor IX biosimilar - Inspiration

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inspiration Biopharmaceuticals
  • Developer Aptevo Therapeutics; Cangene Corporation
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 25 Apr 2018 Aptevo Therapeutics has patent protection for Trenonacog alfa in Australia, Europe and Japan
  • 25 Apr 2018 Aptevo Therapeutics has patents pending for Trenonacog alfa in USA
  • 10 Apr 2017 Pooled efficacy and adverse events data from two clinical trials in Haemophilia B released by Aptevo therapeutics (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top